The goal of functional neuroimaging is to assist in the development of targeted treatments for psychiatric illness.
Functional Neuroimaging: Mapping Psychiatric Illness
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Guidance following the failure of monotherapy when treating depression is limited, as such clinicians usually take a trial and error approach to treatment, a treatment algorithm could help personalise patient care and achieve improved outcomes. It was a pleasure to talk with Dr. Charles Nemeroff (The University of Texas at Austin, Dell Medical School, Austin, […]
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Despite being one of the most common serious psychiatric disorders, major depression remains difficult to treat with only 30-50% of patients achieving remission from monotherapy or talk therapy, however many promising new antidepressants are currently under investigation. We were delighted ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Implementing positive psychiatry approaches can face various barriers across different levels of care. These include resistance to change, limited resources, time constraints, and the dominance of a deficit-focused model. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Positive psychiatry encompasses several approaches that focus on promoting well-being and resilience in mental health care. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how positive ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The discovery of ketamine's therapeutic potential for psychiatric disorders changed the field of mental health, since nearly every FDA-approved medication for schizophrenia and mood disorders targeted monoamine signaling, i.e., dopamine, serotonin, and norepinephrine. As ketamine was initially used as ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The discovery of the rapid antidepressant effects of ketamine shifted the biology and treatment of psychiatric disorders, emphasizing targeting glutamate signaling, rather than monoamine signaling, for schizophrenia and depression. Research highlights synaptic deficits, network disinhibition, and synaptic loss in schizophrenia, ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
touchNEUROLOGY caught up with the INS President, Prof. Marc Russo, to discuss the upcoming congress and what to expect. The International Neuromodulation Society (INS) is excited to announce the relaunch of the in-person INS 15th World Congress in Barcelona, Spain, ...
Mark CompleteCompleted
BookmarkBookmarked
Dr Robert M. Levy (INS Past President) and Dr Carlos Tornero Tornero (Congress Chair) invite you to join the International Neuromodulation Society (INS) 15th World Congress, 21-26 May 2022, held in Barcelona, Spain. The INS 15th World Congress, themed Neuromodulation: From ...
Mark CompleteCompleted
BookmarkBookmarked
Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5...
Mark CompleteCompleted
BookmarkBookmarked
Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5...
Mark CompleteCompleted
BookmarkBookmarked
Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of ...
Mark CompleteCompleted
BookmarkBookmarked
Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of ...
Mark CompleteCompleted
BookmarkBookmarked
TouchNEUROLOGY caught up with Roger McIntyre (University Toronto, Ontario, Canada) to discuss psychedelics, and in particular psilocybin-based therapies, and their potential in the treatment of mood disorders. Questions 1. Please could you give us a brief overview of psilocybin and its ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
